---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-023415"
form_type: "8-K"
ticker: "CLNN"
cik: "0001822791"
company_name: "Clene Inc."
filed_at: "2023-08-14T23:59:59+00:00"
generated_at: "2026-06-11T12:26:27.241813+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Clene reports Q2 net loss of $25.1M; ALS NfL biomarker positive; cash $49.2M

## Summary
- Net loss of $25.1M ($0.29 per share) versus $4.5M loss in Q2 2022; R&D down to $6.6M.
- Cash, equivalents and marketable securities $49.2M after $40M June public offering; potential $130M more from warrants.
- CNM-Au8 reduced plasma neurofilament light chain (NfL) vs placebo (p=0.04) in HEALEY ALS trial at 24 weeks.
- Phase 2 RESCUE ALS results published in Lancet eClinicalMedicine; preparing for FDA ALS regulatory meetings.
- NMSS grant funds Cohort 2 of REPAIR-MS for progressive MS; multiple near-term data announcements expected.

## SEC filing metadata
- accession: 0001437749-23-023415
- form_type: 8-K
- ticker: CLNN
- cik: 0001822791
- company_name: Clene Inc.
- filed_at: 2023-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1822791/000143774923023415/0001437749-23-023415-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1822791/000143774923023415/clnn20230602_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-023415
- JSON: https://secwatch.observer/filing/0001437749-23-023415.json
- Plain text: https://secwatch.observer/filing/0001437749-23-023415.txt

## Key facts
- Earnings Releases
  Clene Inc. reported second quarter 2023 results: net income $25.1 million, EPS $0.29 per share.
  - Period: second quarter 2023
  - Net income: $25.1 million
  - EPS: $0.29 per share
  - Result: reported results
  source text: Clene reported a net loss of $25.1 million , or $0.29 per share, for the quarter ended June 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1822791/000143774923023415/0001437749-23-023415-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.